Filing Details
- Accession Number:
- 0000891293-22-000035
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-07-07 17:02:20
- Reporting Period:
- 2022-07-05
- Accepted Time:
- 2022-07-07 17:02:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 891293 | Cti Biopharma Corp | CTIC | Pharmaceutical Preparations (2834) | 911533912 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1507220 | A Michael Metzger | 3101 Western Avenue Suite 800 Seattle WA 98121 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-07-05 | 91,500 | $0.84 | 111,621 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-07-05 | 8,700 | $5.98 | 102,921 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-05 | 51,963 | $6.05 | 50,958 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-05 | 27,506 | $6.14 | 23,452 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-05 | 3,331 | $6.23 | 20,121 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2022-07-05 | 91,500 | $0.00 | 91,500 | $0.84 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 28,500 | 2029-05-16 | No | 4 | M | Direct |
Footnotes
- This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.95 to $ 5.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.00 to $ 6.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.11 to $ 6.20. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.21 to $ 6.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- The shares underlying the option were fully vested on May 16, 2020, the date that is twelve months after the date of grant.
Billionaire Hedge Funds
